Introduction
Genetic change of p53, whose product is a multifunctional protein exerting a variety of functions in cell cycle control, DNA repair, DNA recombination, initiation of apoptosis and control of dierentiation (Levine, 1997) , is associated with the development of many human cancers including non-small cell lung cancer (NSCLC) and breast cancer (Nigro et al., 1989; Hollstein et al., 1991) . Previous reports show that the frequency of p53 mutation in NSCLC and breast cancer reaches 40*60% (Kishimoto et al., 1990; Takahashi et al., 1989) and 20*50% (Coles et al., 1992; Osborne et al., 1991) , respectively, suggesting that those tumors require p53 mutation to proceed malignant transformation. Indeed, p53 mutation in adenocarcinoma of the lung appeared to result in a poor prognosis (Nishio et al., 1996) . However, the rest of both kinds of tumors progress without any p53 abnormalities.
Recently, novel p53 family genes, p73 and p51/p63, have been discovered (Kaghad et al., 1997; Osada et al., 1998; Yang et al., 1998) . p73 was mapped to 1p36 which is a locus for putative tumor suppressor gene(s) of neuroblastoma and other cancers (Kaghad et al., 1997) . Extensive mutation analyses, however, have revealed that p73 is rarely mutated in many cancers including neuroblastoma (Nomoto et al., 1998; Takahashi et al., 1998; Sunahara et al., 1998; Ichimiya et al., 1999) . Like p53 and p73, p51 also activates the transcription of p21 Waf1/Cip1 and induces apoptosis (Osada et al., 1998) . Furthermore, it has been mapped to chromosome 3q28. Recent genetic analyses including loss of heterozygosity (LOH) and comparative genomic hybridization (CGH) have demonstrated that the long arm of chromosome 3 is frequently rearranged or deleted in NSCLCs (Sato et al., 1994; Petersen et al., 1997) . In addition, p51 is expressed in normal lung and mammary gland (Osada et al., 1998) . These ®ndings stimulated us to test if p51 is related to carcinogenesis of NSCLC and breast cancer.
In the present report, we studied mutation and expression of p51A, an isoform of p51 with short Cterminal region, in 80 NSCLCs and 85 breast cancers. We found three missense and one silent mutations in NSCLC but there were no mutations in breast cancers.
Results and discussion
Eighty tumor tissues of NSCLC were screened for mutation in the coding region of p51A by RT ± PCR ± SSCP and DNA sequencing (Figure 1 ). We used six primer sets shown in Table 1 for the former analysis. Sequencing of the DNA fragments which showed aberrant bands on the PCR ± SSCP gels revealed three missense mutations in three tumors (case numbers of C8, C17 and C47) and a silent mutation in a tumor (C86) ( Table 2) . One of three missense mutations was found in the squamous cell carcinoma of the lung at codon 148 with substitution of Ala to Pro (Figure 1) , the region of which corresponded to the DNA-binding domain of p53. On the database searched, there is no report of mutations at the corresponding codon 119 (Ala) of p53, although it is conserved among p53, p51 and p73. Two others were found in adenocarcinomas as with the same mutation from Gln to His at codon 31 in the transactivation domain. We next examined mutations and/or polymorphisms of the entire coding region of the p51A gene by RT ± PCR ± SSCP method using 23 normal tissues including 11 lungs, eight gastric mucosae, three colonic mucosae and one placenta. However, none of these showed any bandshifts on the PCR ± SSCP gels (data not shown).
To assess whether or not the p51A mutations found in NSCLCs are loss of function, we used modi®ed FASAY method (Ishioka et al., 1993 (Ishioka et al., , 1995 , a yeast functional assay system, which tests the ability of yeast expressing p51A cDNA to grow in medium lacking histidine (His + ). The plasmid, pCIP51, was constructed by inserting the p51A fragment into the pCI53Y3 vector. When the YCI-1 was transformed by the pCIP51, the transformants grew in medium lacking histidine (His + ), indicating that p51A acts as a transcriptional activator through the p21 Waf1/Cip1 promoter in yeast as in the case of p53 ( Figure  2) . Then, the two mutant p51A expression vectors were also tested in the same strain. The pCIP51(Gln31His) produced His + transformants, indicating that p51A(Gln31His) retains normal p51 activity. In contrast, the pCIP51(Ala148Pro) produced His 7 transformants, indicating that p51A(Ala148Pro) lacks normal p51 activity. These results suggest that Ala148Pro is a pathogenic mutation, although this case is also associated with the p53 mutation in the DNA-binding domain. A role of Gln31His mutation in lung carcinogenesis awaits further study because this mutation is functional in FASAY assay. Nevertheless, there were no such mutations in more than three hundred tumor cases (S Ikawa, personal communication), and this mutation may have some biological meaning.
In the C8 NSCLC (78-year-old, a smoker), all ®ve clones picked up are the same mutants ( Table 2 ), suggesting that there is an allelic loss of p51 with expressing the mutant form transcript from the retained allele, or that it is monoallelically expressed from the mutated allele. Interestingly, p53 of this tumor was also mutated at codon 157 from Val(GTC) to Phe(TTC) in the DNA binding domain (data not shown). These suggest that the tumor is rather aggressive. Indeed, it was a stage 3 tumor with metastasis to the mediastinal lymph nodes, although the size of the primary tumor in the S1 region of right 
Sq, sqamous cell carcinoma; Ad, adenocarcinoma; mut, mutation; n.d., not determined lung was not so large (32625 mm). The patient died of the disease with pleural eusion 8 months after the diagnosis. On the other hand, both tumors with a Gln31His mutation were adenocarcinoma of the lung, and p53 was not mutated in C17. It is intriguing that Gln31His is a mutation in the transactivation domain which is rare in those of p53 (Levine, 1997) . In addition, from the sequence similarity between p51A and p53, the site of codon 31 of p51A may possibly be involved in the Mdm2-binding region if Mdm2 could interact with p51A. Then, the missense mutation of the codon 31 may aect the binding without interfering with the transactivation function. Since only mutated form of transcripts appears to be predominantly expressed in C8, C47 and C86 (Table 2) , there may be certain percentage of p51 LOH or imprinting of the p51 gene. The levels of p51 mRNA expression were examined in 24 NSCLC samples by semi-quantitative RT ± PCR method (changing the PCR cycles: 20, 25, 30 and 35) using a primer pair designed in the DNA-binding domain. p51 mRNA was ubiquitously expressed in NSCLCs, although the levels were variable (Figure 3a) . There appeared no signi®cant correlation between levels of p51 expression and several clinicopathological variables including age, sex, tumor stage and histology (data not shown). Eight paired tumor and corresponding normal lung tissues were subjected to the comparison of p51 expression. We found no correlation between the levels of p51 mRNA expression in NSCLC tumor and the adjacent normal tissue (Figure 3b) .
The same RT ± PCR ± SSCP method was applied to search mutation of p51A in 85 breast cancers. To increase the sensitivity and reliability, we used uorescence-labeled primers in the multiplex system, in addition to using radioisotope (Figure 4b ). However, we found no aberrant bands on the gels. Thus, unlike NSCLCs, mutation of p51A is very rare or absent in breast cancers. On the other hand, like NSCLCs, p51 mRNA was ubiquitously expressed at variable levels in 85 breast cancers as shown in Figure 4a .
Thus, our present study has revealed that mutation of p51A is infrequent in both NSCLCs and breast cancers, although information about the presence or absence of p51 LOH was not available. This suggests that p51 may not be a tumor suppressor gene ®tting to the Knudson's two-hit model. Nevertheless, we found some missense mutations in NSCLC but not in breast cancer, suggesting that p51 still acts as a tumor suppressor in at least a small part of NSCLCs. The expression pro®le of the p51A mutants shown in Table  2 suggests the probability of the presence of LOH and/ or imprinting of the p51 gene in NSCLCs, which should be further examined.
Wild type p51 is expressed at variable levels in most of NSCLCs and breast cancers. The previous reports have demonstrated that there are some splicing variants of p51/p63 and the N-terminal-truncated variants act as a dominant-negative form (Yang et al., 1998) , suggesting that the levels of each alternatively spliced form of the p51/p63 transcripts might be important in regulating carcinogenesis. Furthermore, there is a report describing impairment of p73 function by mutant p53 in tumor cells (Di Como et al., 1999) , and hetero-oligomerization among wild type and mutant p51, p73 and p53 may also aect the growth and apoptosis of the tumor. Those analyses are currently being underway in NSCLC and breast cancer.
Materials and methods

Tissue specimens
Surgically resected tumor tissues were obtained from 80 Japanese patients (33 ± 84 years old) with NSCLC. Thirtyfour frozen tissues were given from the Chiba Cancer Center Tissue Bank. All samples were obtained before receiving chemotherapy and/or radiation therapy. The corresponding normal lung tissues were obtained from the same lobe more than 3 cm distant from the tumor margin in 11 cases. Histologically, the NSCLCs consisted of 43 adenocarcinomas, 30 squamous cell carcinomas, four large cell carcinomas and three adenosquamous carcinomas.
Fresh tumor tissues and their adjacent normal breast tissues used in this study were obtained from 85 patients treated at the Chiba Cancer Center Hospital between November 1996 and September 1997. The median age of the patients was 51 years (23 ± 80), and the median tumor size 30 mm (8 ± 52). Tumors were diagnosed according to the histologic typing scheme of the Japanese Breast Cancer Society (1989) which is essentially the same as that of the World Health Organization: 31 invasive papillotubular types (2a1), 17 invasive solid tubular types (2a2), 32 invasive scirrhous carcinomas (3a3), and ®ve other speci®c types (b Group).
RT ± PCR analysis
Total RNA was extracted from tumor tissues and their corresponding normal tissues, as described previously (Sunahara et al., 1998) . Five mg of total RNA was converted to cDNA by using random primers (TAKARA, Otsu, Japan) and Superscript II reverse transcriptase (Life Technologies Inc., Gaithersberg, MD, USA). One twentieth of the ®nal volume of the RT reaction mixture was subjected to polymerase chain reaction (PCR). The 20 ml of PCR reaction mixture contained 1 mM each primer, 200 mM deoxynucleotide triphosphates (dNTPs), 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl 2 and 1.4 units DNA polymerase (Expand High Fidelity PCR system, Boehringer Mannheim, Mannheim, Germany). PCR was performed as follows: preheating at 968C for 3 min followed by 35 cycles of 968C for 30 s, 538C for 30 s, and 728C for 1 min with ®nal extension at 728C for 5 min, using a thermocycler (Perkin-Elmer Cetus, Foster City, CA, USA). The PCR products were run on agarose gels and visualized with an UV illuminator. To examine p51 mRNA expression, we used a primer pair of p51A2F and p51A2R in Table 1 which ampli®ed the region including a part of the DNA-binding domain of p51 (codon 80 ± 177). For RT ± PCR of GAPDH as a control, we used a forward primer: 5'-ACCACAGTCCATGCCATCAC-3' and a reverse primer: 5'-TCCACCACCCTGTTGCTGTA-3', giving a 451 bp product size. For semi-quantitative analysis of RT ± PCR, the number of PCR cycle was changed to 20, 25, 30 and 35.
RT ± PCR ± SSCP and DNA sequencing
To screen mutation in the coding region of p51A, RT± PCR ± SSCP (Orita et al., 1989) was performed with 6 primer pairs shown in Table 1 . The 5 ml reaction mixture contained 1 ml of the cDNA synthesized, 1 mM of each primer, 200 nM dNTPs, 16buer, 0.15 units DNA polymerase (Expand High Fidelity PCR system) and [a-32 P]dCTP. PCR was performed as follows: preheating at 968C for 3 min followed by 35 cycles of 968C for 30 s, 538C for 30 s and 728C for 1 min with ®nal extension at 728C for 5 min. PCR products were mixed with 10 times volume of a loading buer containing 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol, denatured at 988C for 5 min, quenched on ice, and electrophoresed on 5% polyacrylamide gels with 5% glycerol at 200 V for 16 h at room temperature. Then, the gels were exposed to X-ray ®lm overnight at 7808C. To determine DNA sequences of the PCR products, they were subcloned into pGEM-T Easy Vector (Promega, Madison, WI, USA), and those fragments were sequenced by the dideoxynucleotide method, using the ABI 377 automatic DNA sequencer (Perkin-Elmer Cetus). The PCR ± SSCP was also performed by using a¯uorescence-labeled primers under the similar PCR conditions, and then analysed by ALFexpress DNA sequencer (Amersham Pharmacia Biotech AB, Uppsula, Sweden).
p51A yeast functional assay
The p51 status was assayed by testing the ability of yeast expressing p51A cDNA to grow in medium lacking histidine (His + ) by using the modi®ed FASAY method described previously (Ishioka et al., 1993) . Brie¯y, a p51 cDNA, containing full length open reading frame of p51A sequence, was ampli®ed by PCR using a set of primers, 5'-actagaaataattttgtttaactttaagaaggaga-tatacggatccatgtccagagcacacagac-3', and 5'-tgggaggctgtcagcgg-ggaacaagaagtggagaatgtcaagcttctatgggtacactgatcggt-3'. pCIP51 was constructed by inserting the p51A fragment into BamHI/HindIII site of pCI53Y3 (Ishioka et al., 1995) . This vector expresses a wildtype p51A under the control of ADH1 promoter, and was used as a positive control. pCIP51(Gln31His) and pCIP51(Ala148Pro) were constructed from partial p51A fragments derived from lung cancers using a gap repair technique. These vectors were identical to pCIP51 except that the codon 31 and the codon 148 of p51A cDNA were replaced by glutamine to histidine, and alanine to proline, Figure 4 Expression and no mutation of p51A in breast cancers. (a) p51 was expressed at variable levels in all breast cancers (using a primer set 2). PCR cycles: 35 cycles for p51, and 30 cycles for GAPDH. (b) RT ± PCR ± SSCP analysis of p51 in breast cancers. A primer set 2 in Table 1 was used respectively, and should express mutant form of p51A protein. The speci®c p51 mutations of pCIP51(Gln31His) and pCIP51(Ala148Pro) were con®rmed by sequencing analysis using BigDye TM terminator cycle sequencing kit (Applied Biosystem) and ABI Prism TM 310. A reporter plasmid, pCI-WAFP(HIS), was constructed by inserting a p21 Waf1/Cip1 promoter fragment (Genbank U24170: nt. 2242 ± 3258), which contains two p53 binding sites, into a EcoRI site of pBM2389 (a gift from M Johnston). The yeast strain, YCI-1, is identical to ySS5 except that the pSS1 was replaced by the pCI-WAFP(HIS).
